Alvotech Study: Therapeutic Equivalence of Biosimilar Candidate AVT06, Reference Product Eylea

 The confirmatory clinical, safety and efficacy study for AVT06, biosimilar candidate to Eylea® (aflibercept) met its primary endpoint in patients with neovascular (wet) Age-related Macular Degeneration (AMD)

https://www.globenewswire.com/news-release/2024/01/03/2803066/0/en/Alvotech-Clinical-Study-Results-Demonstrate-Therapeutic-Equivalence-between-Biosimilar-Candidate-AVT06-and-Reference-Product-Eylea-aflibercept.html